Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics
Mie Fabricius Pedersen(University of Copenhagen), Hans Bräuner‐Osborne(University of Copenhagen), Dariusz Matosiuk(Medical University of Lublin), Thor C. Møller(University of Copenhagen), Tomasz M. Wróbel(University of Copenhagen), Federica Gabriele(University of Copenhagen), Henrik Pedersen(Lundbeck (Denmark)), Emil Märcher-Rørsted(University of Copenhagen), Michel Bouvier(Institute for Research in Immunology and Cancer), Simon R. Foster(University of Copenhagen), Daniel Sejer Pedersen(University of Copenhagen)
Cited by 81
Related Papers
Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants
|Journal of Clinical Investigation|2000|561
Ligands for Glutamate Receptors: Design and Therapeutic Prospects
|Journal of Medicinal Chemistry|2000|525
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors
|Nature Communications|2012|483
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390